Mineralys Therapeutics, Inc.
MLYS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 331.8% and free cash flow fell 7.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow MLYS
Mineralys Therapeutics, Inc. (MLYS) Altman Z-score
Altman Z-score, annual
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ZYME Zymeworks Inc. compare | 11.6× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 8.4× |
| AGIO Agios Pharmaceuticals, Inc. compare | 8.1× |
| MESO Mesoblast Limited compare | 3.4× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 0.4× |
| SRPT Sarepta Therapeutics, Inc. compare | −1.0× |
| URGN Urogen Pharma compare | −5.2× |
| PVLA Palvella Therapeutics, Inc. compare | −11.5× |
| MLYS Mineralys Therapeutics, Inc. | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets